clinical trial · NCT06682572
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
Low Grade Serous Ovarian CancerOvarian CancerAvutometinib (VS-6766) + Defactinib (VS-6063)
brief summary
This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
started
Oct 30, 2024
primary completion
Dec 1, 2025
completion
Oct 1, 2027
last updated
Dec 17, 2025
detailed description
This is a multi-center, open label Phase 2 study designed to evaluate safety and tolerability and confirm efficacy by BICR of avutometinib in combination with defactinib in Japanese patients with molecularly profiled recurrent LGSOC.
official title
A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Japanese Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol